Ordinary water carrying dissolved hydrogen gas, prepared from a tablet or a small electrolysis device. Strongest findings are modest: cholesterol falls slightly, effort feels easier during exercise, jump power improves. The same data show protective cholesterol dipping. Larger trials found nothing for blood-sugar handling, endurance or strength. Safety record is clean; long-term data thin. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | Below 80 mg/dL | The endpoint with the strongest pooled evidence of change |
| HDL cholesterol | Above 55 mg/dL (men), above 65 mg/dL (women) | Pooled data show a small reduction, the one adverse lipid signal |
| Total cholesterol | 150–200 mg/dL | The lipid fraction with the largest measured reduction |
| Triglycerides | Below 80 mg/dL | Showed the largest pooled effect size of any lipid measure |
| Glycated haemoglobin | 4.8–5.3% | Three-month average blood sugar; reduced in the 24-week metabolic-syndrome trial |
| Fasting insulin | Below 6 µIU/mL | The insulin-resistance endpoint that failed when tested directly |
| Alanine aminotransferase | Below 25 U/L (men), below 20 U/L (women) | Liver enzyme reduced modestly in pooled trials; tracks the liver-fat finding |
| High-sensitivity C-reactive protein | Below 0.5 mg/L | General inflammation marker; the proposed mechanism should move it if anything does |
| Serum magnesium | 2.0–2.4 mg/dL | Safety check for tablet users, whose formulations deliver magnesium with every dose |
| Estimated glomerular filtration rate | Above 90 mL/min/1.73 m² | Determines whether the magnesium load from tablets is safely cleared |
| Dissolved hydrogen delivered | No established target; 0.3–7.5 millimolar trial range | Dose is the single largest source of variation across trials |
Cadence: Lipid panel and liver enzymes at 8–12 weeks; glycated haemoglobin and fasting insulin at 12–24 weeks; then all of them every 6–12 months where use continues. Serum magnesium and kidney function annually for tablet users.